Ayvakyt
avapritinib
Table of contents
Overview
Ayvakyt is a cancer medicine used to treat gastrointestinal stromal tumour (GIST), a cancer of the stomach and bowel, that cannot be removed by surgery and has spread to other parts of the body. Ayvakyt is used when the cancer cells have a D842V mutation, a change in the gene for the platelet-derived growth factor receptor alpha (PDGFRA).
Ayvakyt is also used in adults with advanced systemic mastocytosis, which means any of the following disorders of a type of white blood cell known as mast cells: aggressive systemic mastocytosis, systemic mastocytosis associated with a haematological neoplasm (blood cancer), or mast cell leukaemia. It is used after the patient has received at least one systemic treatment (treatment with medicines affecting the whole body).
These diseases are rare, and Ayvakyt was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 July 2017 (GIST) and on 26 October 2018 (mastocytosis).
Ayvakyt contains the active substance avapritinib.
-
List item
Ayvakyt : EPAR - Medicine overview (PDF/115.64 KB)
First published: 30/09/2020
Last updated: 18/05/2022
EMA/68210/2022 -
-
List item
Ayvakyt : EPAR - Risk-management-plan summary (PDF/165.07 KB)
First published: 30/09/2020
Last updated: 18/05/2022
Authorisation details
Product details | |
---|---|
Name |
Ayvakyt
|
Agency product number |
EMEA/H/C/005208
|
Active substance |
avapritinib
|
International non-proprietary name (INN) or common name |
avapritinib
|
Therapeutic area (MeSH) |
Gastrointestinal Stromal Tumors
|
Anatomical therapeutic chemical (ATC) code |
L01EX18
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Conditional approval |
This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation. |
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Blueprint Medicines (Netherlands) B.V.
|
Revision |
7
|
Date of issue of marketing authorisation valid throughout the European Union |
24/09/2020
|
Contact address |
Gustav Mahlerplein 2 |
Product information
26/05/2023 Ayvakyt - EMEA/H/C/005208 - II/0022
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Other antineoplastic agents
-
Protein kinase inhibitors
Therapeutic indication
Ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.
Assessment history
News
-
10/11/2023
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 202228/01/2022
-
24/07/2020